Survival Analysis of Fuzhong Xiaoji Staging Therapy for Rectal Cancer

Lan ZHENG,Lingling LYU,Haifeng YING,Yuanbiao GUO,Weiyu ZHANG,Jingxian CHEN,Xiaoheng SHEN
DOI: https://doi.org/10.13194/j.issn.1673-842x.2018.01.003
2018-01-01
Abstract:Objective:This study was to explore the impact on survival by Fuzhong Xiaoji (FZXJ) staging therapy in rectal cancer patients.Methods:By the method of retrospective cohort and selected into the group of 149 cases of rectal cancer patients.97 patients were collected in the treatment group (treated with FZXJ staging therapy)and 52 patients were collected in the control group (treated without FZXJ staging therapy).Overall survival,median overall survival and disease free survival,progress free survival and the starting time and lasting time of using Chinese medicine were all observed.The cases were also analysised by multiple factor COX regression method.Results:By COX regression analysis,the factor of influence are the tumor stage and the time of taking Chinese medicine.Protection factor was taking Chinese medicine time,risk factor was the tumor stage.The difference was statistically significant (P<0.01);Compared two groups of patients survival time,the OS of the control group was (67.0 ± 0) months,The OS of the treatment group was (111.61 ± 6.39) months,the difference was statistically significant (P<0.01);DFS in the two group in the stage of Ⅱ,Ⅲ was statistically significant different (P<0.01).PFS in the two group in the stage of Ⅳ was no statistically significant different (P>0.05).OS had statistically significant difference both in the group by not taking Chinese medicine,taking Chinese medicine after operations,taking Chinese medicine after chemotherapy and taking Chinese medicine after recurrence and metastasis.Conclusion:Overall survival of the patients in rectal cancer can be prolonged by using FZXJ staging therapy.The rate of recurrence and metastasis in stages Ⅱ-Ⅲ can be reduced,PFS in stage Ⅳ patients can be extended,OS can be prolonged both after operations and chemotherapy by also using FZXJ staging therapy.Protection factor is taking Chinese medicine time,risk factor is the tumor stage.
What problem does this paper attempt to address?